Psychedelics vs. Cannabis: Which Is Better for Mental Health?

As the global mental health crisis intensifies, researchers are exploring previously prohibited substances like cannabis and psychedelics as potential therapeutic interventions. Both compounds show promise for treating various psychiatric conditions, but they work through different mechanisms and carry distinct risk-benefit profiles. Cannabis primarily affects the endocannabinoid system and may provide symptom relief, while psychedelics like psilocybin and LSD appear to facilitate neuroplasticity and psychological insight. The COVID-19 pandemic has accelerated research into alternative mental health treatments, revealing significant gaps in conventional approaches. Understanding the nuanced differences between these therapies is essential for patients and healthcare providers considering evidence-based treatment options.